@article{4e71856913b14d568e1120d904727aaf,
title = "Self-expanding transcatheter aortic valve replacement using alternative access sites in symptomatic patients with severe aortic stenosis deemed extreme risk of surgery",
abstract = "Objectives The CoreValve Extreme Risk US Pivotal Trial enrolled patients with symptomatic severe aortic stenosis deemed unsuitable for surgical aortic valve replacement. Implants were attempted using transfemoral access (n = 489) or an alternative access (n = 150). In present analysis, we sought to examine the safety and efficacy of CoreValve transcatheter aortic valve replacement using alternative access.Results The preoperative aortic valve area was 0.72 ± 0.27 cm2 and mean aortic valve gradient was 49.5 ± 17.0 mm Hg. After the transcatheter aortic valve replacement, the effective aortic valve area was 1.82 ± 0.64 cm2 at 1 month and 1.85 ± 0.51 cm2 at 12 months. The mean aortic valve gradient was 9.7 ± 5.8 mm Hg at 30 days and 9.5 ± 5.7 mm Hg at 12 months. The death or major stroke rate was 15.3% at 30 days and 39.4% at 12 months. The individual rate of all-cause mortality and major stroke was 11.3% and 7.5% at 30 days and 36.0% and 9.1% at 12 months.Conclusions These data demonstrate that the CoreValve transcatheter heart valve delivered by an alternative access provides a suitable alternative for treatment of extreme risk patients with symptomatic severe aortic stenosis, who have prohibitive iliofemoral anatomy and no surgical options.",
author = "Reardon, {Michael J.} and Adams, {David H.} and Coselli, {Joseph S.} and Deeb, {G. Michael} and Kleiman, {Neal S.} and Stan Chetcuti and Yakubov, {Steven J.} and David Heimansohn and James Hermiller and Hughes, {G. Chad} and Harrison, {J. Kevin} and Kamal Khabbaz and Peter Tadros and Zorn, {George L.} and William Merhi and John Heiser and George Petrossian and Newell Robinson and Brijeshwar Maini and Mubashir Mumtaz and Lee, {Joon Sup} and Gleason, {Thomas G.} and Jon Resar and John Conte and Daniel Watson and Sharla Chenoweth and Popma, {Jeffrey J.}",
note = "Funding Information: Disclosures: Michael J. Reardon reports consulting fees from Medtronic. Joseph S. Coselli reports consulting fees for Medtronic and St Jude Medical, and grant support from Medtronic and Edwards Lifesciences. James Hermiller reports consulting fees from Medtronic, Abbott, and St Jude Medical. G. Chad Hughes reports consulting fees for Medtronic and W.L. Gore and lecture fees from Medtronic, W. L. Gore, and Vascutek. Brijeshwar Maini reports consulting fees for and lecture fees from St Jude Medical, Medtronic, and Abbott Vascular. Jon Resar reports grant support from Medtronic and Abbott Vascular. Sharla Chenoweth reports equity ownership in Medtronic. David Heimansohn reports lecture fees from Edwards Lifesciences. Steven J. Yakubov reports consulting fees from Boston Scientific and Medtronic. John Conte reports lecture fees from Medtronic. George L. Zorn III reports consulting fees from Medtronic and Edwards. Stan Chetcuti reports consulting fees from Medtronic and Edwards. Peter Tadros reports consulting and lecture fees from Medtronic, Edwards, and St Jude Medical. Jeffrey J. Popma reports consulting fees for Boston Scientific, Covidien, and Abbott Vascular; lecture fees from Boston Scientific; and grant support from Medtronic. Newell Robinson reports consulting fees from Medtronic. All other authors have nothing to disclose with regard to commercial support. ",
year = "2014",
month = dec,
day = "1",
doi = "10.1016/j.jtcvs.2014.07.020",
language = "English (US)",
volume = "148",
pages = "2869--2876.e7",
journal = "Journal of Thoracic and Cardiovascular Surgery",
issn = "0022-5223",
publisher = "Mosby Inc.",
number = "6",
}